Literature DB >> 9479578

Structure-based design of immunologically active therapeutic peptides.

R Murali1, M I Greene.   

Abstract

Peptides are flexible molecules and can adopt local structural features of protein, such as secondary structure, hydrophobicity, and distribution of electrostatic charges, and so forth, and mimic their functions. Therapeutic peptidomimetics that are immunologically relevant are developed by engineering the surface loop structures in the proteins and receptors. The class of molecules targeted include immunoglobulin fold-containing molecules: antibody, cell-surface CD4 receptors and cystine-knot-containing receptor family members: tumor necrosis factor (TNF), CD40, and p185/Neu receptors. We have used the loops involved in the molecular recognition as a template and developed peptidomimetics that interfere with the functions of the target molecules. In this article, two molecular targets are discussed: (1) immunoglobulin fold-containing CD4 receptor and (2) cystine-knot-containing TNF receptor (TNFR).

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9479578     DOI: 10.1007/BF02786441

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  50 in total

1.  An efficient phage plaque screen for the random mutational analysis of the interaction of HIV-1 gp120 with human CD4.

Authors:  P Tsui; R W Sweet; G Sathe; M Rosenberg
Journal:  J Biol Chem       Date:  1992-05-05       Impact factor: 5.157

2.  ABGEN: a knowledge-based automated approach for antibody structure modeling.

Authors:  C Mandal; B D Kingery; J M Anchin; S Subramaniam; D S Linthicum
Journal:  Nat Biotechnol       Date:  1996-03       Impact factor: 54.908

3.  Synthetic CD4 exocyclics inhibit binding of human immunodeficiency virus type 1 envelope to CD4 and virus replication in T lymphocytes.

Authors:  X Zhang; M Gaubin; L Briant; V Srikantan; R Murali; U Saragovi; D Weiner; C Devaux; M Autiero; D Piatier-Tonneau; M I Greene
Journal:  Nat Biotechnol       Date:  1997-02       Impact factor: 54.908

Review 4.  The TNF ligand superfamily and its relevance for human diseases.

Authors:  H J Gruss; S K Dower
Journal:  Cytokines Mol Ther       Date:  1995-06

5.  Structure of antibody hypervariable loops reproduced by a conformational search algorithm.

Authors:  R E Bruccoleri; E Haber; J Novotný
Journal:  Nature       Date:  1988-10-06       Impact factor: 49.962

6.  A 20 amino acid synthetic peptide of a region from the 55 kDa human TNF receptor inhibits cytolytic and binding activities of recombinant human tumour necrosis factor in vitro.

Authors:  C D Hwang; M Gatanaga; E K Innins; R S Yamamoto; G A Granger; T Gatanaga
Journal:  Proc Biol Sci       Date:  1991-08-22       Impact factor: 5.349

Review 7.  Considerations in the design and production of small anti-receptor antibody forms: optimizing gains while reducing size.

Authors:  N C Peterson; M I Greene
Journal:  Ther Immunol       Date:  1994-10

8.  Identification and characterization of a TNF alpha antagonist derived from a monoclonal antibody.

Authors:  E Döring; R Stigler; G Grütz; R von Baehr; J Schneider-Mergener
Journal:  Mol Immunol       Date:  1994-10       Impact factor: 4.407

9.  The structure of human lymphotoxin (tumor necrosis factor-beta) at 1.9-A resolution.

Authors:  M J Eck; M Ultsch; E Rinderknecht; A M de Vos; S R Sprang
Journal:  J Biol Chem       Date:  1992-02-05       Impact factor: 5.157

10.  Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric FV fragments with high avidity in Escherichia coli.

Authors:  P Pack; A Plückthun
Journal:  Biochemistry       Date:  1992-02-18       Impact factor: 3.162

View more
  8 in total

1.  The role of distinct p185neu extracellular subdomains for dimerization with the epidermal growth factor (EGF) receptor and EGF-mediated signaling.

Authors:  T Kumagai; J G Davis; T Horie; D M O'Rourke; M I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

Review 2.  Targeting erbB receptors.

Authors:  Zheng Cai; Hongtao Zhang; Jing Liu; Alan Berezov; Ramachandran Murali; Qiang Wang; Mark I Greene
Journal:  Semin Cell Dev Biol       Date:  2010-09-17       Impact factor: 7.727

3.  Matching organic libraries with protein-substructures.

Authors:  R Preissner; A Goede; K Rother; F Osterkamp; U Koert; C Froemmel
Journal:  J Comput Aided Mol Des       Date:  2001-09       Impact factor: 3.686

Review 4.  Rational Design of Constrained Peptides as Protein Interface Inhibitors.

Authors:  Ramachandran Murali; Hongtao Zhang; Zheng Cai; Lian Lam; Mark Greene
Journal:  Antibodies (Basel)       Date:  2021-08-16

5.  Role of extracellular subdomains of p185c-neu and the epidermal growth factor receptor in ligand-independent association and transactivation.

Authors:  Toru Kumagai; Makoto Katsumata; Akihiro Hasegawa; Keiji Furuuchi; Toshiki Funakoshi; Ichiro Kawase; Mark I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-16       Impact factor: 11.205

Review 6.  The TNF receptor superfamily: role in immune inflammation and bone formation.

Authors:  Xin Cheng; Masa Kinosaki; Ramachandran Murali; Mark I Greene
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

Review 7.  Structure-based approaches to inhibition of erbB receptors with peptide mimetics.

Authors:  Alan Berezov; Mark I Greene; Ramachandran Murali
Journal:  Immunol Res       Date:  2003       Impact factor: 4.505

8.  Structure based antibody-like peptidomimetics.

Authors:  Ramachandran Murali; Mark I Greene
Journal:  Pharmaceuticals (Basel)       Date:  2012-02-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.